Peptide questions · Enicepatide
Enicepatide side effects: what studies and users report
Reviewed Evidence: ModeratePublished by PepVault
The side effects most commonly reported for enicepatide are nausea, constipation and diarrhea, among 4 the library lists; the library’s evidence on it includes controlled trials in people.
Its safety note opens: enicepatide has no label: it is still in trials.
What is commonly reported with enicepatide
- Nausea
- Constipation
- Diarrhea
- Vomiting
Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.
| Effect | Also listed for (of 24) |
|---|---|
| Nausea | 21: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 17 more |
| Constipation | 13: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 9 more |
| Diarrhea | 20: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 16 more |
| Vomiting | 18: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 14 more |

Model. Individual results vary.
Which enicepatide side effects the metabolic & GLP-1 group shares
Across the 25 metabolic & GLP-1 compounds in the library, the effects listed most often are nausea (22 of 25), diarrhea (21 of 25), vomiting (19 of 25) and constipation (14 of 25). Every effect on enicepatide’s list also appears for at least one other metabolic & GLP-1 compound, so nothing on it is enicepatide’s own.
What the enicepatide safety notes say
The library’s safety note
Enicepatide has no label: it is still in trials. In the 48-week obesity phase 2 trial, most side effects were GI (nausea, constipation, diarrhea, vomiting) and mild to moderate, in line with the incretin class; 5.9% on enicepatide stopped for side effects vs 1.3% on placebo, and serious events were low and not dose-related, with no grade 4 or 5 events. In the diabetes phase 2 trial, 2.0% stopped for side effects vs 0% on placebo. It is a GLP-1 drug, so the class warnings in GLP-1 labels (including pancreatitis, gallbladder disease and the rodent thyroid C-cell finding) are the ones to read. These are trial findings to review with your clinician.
The library’s interaction note
No interaction studies have been published. GLP-1 drugs slow stomach emptying, which can change how oral medicines are absorbed. It is a GLP-1 drug itself, so it is not stacked with another one. Roche plans to test it with its amylin drug petrelintide. With insulin or a sulfonylurea, discuss glucose monitoring with your clinician.
These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.
Where the enicepatide reports come from
The library rates the evidence on enicepatide as moderate: animal studies plus some human data.
Of the library’s 7 research notes on enicepatide, 5 rest on randomized trials, 1 on clinical data and 1 on community reports.
Our 1 study page on enicepatide: 1 randomized trial.
So enicepatide has controlled trials in people to set its listed effects against.
What our enicepatide study pages report on safety
Enicepatide: -4.7% to -8.0% body weight change by day 29 in phase 1
Randomized trial, human, 2026: Most side effects were mild or moderate, and the safety pattern matched other incretin-based medicines. This is an early human result for enicepatide: weight loss and better blood sugar over 4 weeks, with side effects similar to other drugs in its class.
Questions people ask
What are the side effects of enicepatide?
The side effects most commonly reported for enicepatide are nausea, constipation and diarrhea, among 4 the library lists; the library’s evidence on it includes controlled trials in people.
Do enicepatide’s side effects come from human studies?
The library rates the evidence on enicepatide as moderate, and the library’s evidence on it includes controlled trials in people.
Which enicepatide side effects are its own?
None: each effect the library lists for enicepatide is listed for at least one other metabolic & GLP-1 compound too.
Does enicepatide interact with other medicines?
The library’s interaction note on enicepatide begins: No interaction studies have been published.